Biohaven Ltd. Files 8-K

TL;DR

Biohaven filed an 8-K, standard procedure, check for details.

AI Summary

Biohaven Ltd. filed an 8-K on April 22, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial details or significant corporate actions beyond routine reporting requirements.

Why It Matters

This filing indicates Biohaven Ltd. is meeting its regulatory reporting obligations. Investors should review the full document for any specific disclosures that may impact the company.

Risk Assessment

Risk Level: low — The filing is a routine 8-K and does not disclose any new material risks or events.

Key Players & Entities

• Biohaven Ltd. (company) — Registrant
• April 22, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $41.00 — mon shares, at a price to the public of $41.00 per common share. On April 22, 2024, th
• $264.5 million — able by the Company, were approximately $264.5 million. The Underwriting Agreement contains c

Filing Documents

• bhvn-20240422.htm (8-K) — 26KB
• exhibit11-closing8xk42224.htm (EX-1.1) — 250KB
• exhibit51-closing8xk42224.htm (EX-5.1) — 28KB
• mapleslogo.jpg (GRAPHIC) — 51KB
• 0001628280-24-017139.txt ( ) — 549KB
• bhvn-20240422.xsd (EX-101.SCH) — 2KB
• bhvn-20240422_lab.xml (EX-101.LAB) — 21KB
• bhvn-20240422_pre.xml (EX-101.PRE) — 12KB
• bhvn-20240422_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On April 17, 2024, Biohaven Ltd. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, as representative of the several underwriters named therein, in connection with the registered public offering (the "Offering") of up to 6,451,220 of the Company's common shares, including the underwriters' option to purchase 841,463 additional common shares, at a price to the public of $41.00 per common share. On April 22, 2024, the Company issued and sold 6,451,220 of its common shares pursuant to the Underwriting Agreement, which included the exercise in full of the underwriters' option to purchase additional common shares. The aggregate gross proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, were approximately $264.5 million. The Underwriting Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties and termination provisions. A copy of the underwriting agreement is attached as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein. The Offering was made pursuant to an effective shelf registration statement (the "Registration Statement") filed with the Securities and Exchange Commission on October 2, 2023 (File No. 333-274822), a base prospectus, dated October 2, 2023, included as part of the Registration Statement, and a prospectus supplement, dated April 17, 2024, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended. A copy of the opinion of Maples & Calder relating to the issuance of the common shares in the Offering is attached hereto as Exhibit 5.1 to this Current Report on Form 8-K. Exhibits 1.1 and 5.1 hereto are hereby incorporated by reference into the Registration Statement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated as of April 17, 2024, by and between the Company and J.P. Morgan Securities LLC, as representative of the several underwriters. 5.1 Opinion of Maples & Calder. 23.1 Consent of Maples & Calder (included in Exhibit 5.1). 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biohaven Ltd. By: /s/ Vlad Coric, M.D. Date: April 22, 2024 Vlad Coric, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR